EANM 程序指南:动脉内放射性化合物治疗肝癌与肝转移
欧洲核医学协会(EANM)发布程序指南,旨在协助核医学科医生治疗与管理接受放射性栓塞治疗的患者。指南指出,对于原发性肝癌(肝细胞癌或肝内胆管癌)及肝转移瘤,放射性栓塞已被证明是安全有效的治疗选择,个体化剂量学可显著提高缓解率和总生存期。放射性栓塞的决策应由多学科肿瘤委员会根据现行临床指南作出。
要点
- 放射性栓塞对原发性肝癌和肝转移瘤是安全有效的治疗选择。
- 个体化剂量学可显著提高缓解率和总生存期。
- 放射性栓塞的决策应由多学科肿瘤委员会根据现行临床指南作出。
核心结论
- 放射性栓塞已被证明是原发性肝癌和肝转移瘤的安全有效治疗选择。
- 个体化剂量学具有巨大潜力,可显著提高缓解率和总生存期。
- 放射性栓塞的决策应由多学科肿瘤委员会根据现行临床指南作出。
研究设计与样本
- 本指南由欧洲核医学协会(EANM)制定,旨在协助核医学科医生治疗和管理接受放射性栓塞治疗的患者。
- EANM 成立于1985年,是一个非营利性专业医学协会,致力于促进全球核医学临床与研究卓越者之间的交流。
主要发现
- 原发性肝癌(肝细胞癌或肝内胆管癌)中仅10-20%的患者适合接受切除或移植等治愈性治疗。
- 肝转移瘤最常由结直肠癌引起,结直肠癌在欧洲是第二大致死性癌症。
- 放射性栓塞已被证明是原发性和继发性肿瘤的安全有效治疗选择。
- 个体化剂量学已显示出巨大潜力,可显著提高缓解率和总生存期。
关键数值与推荐
- 放射性栓塞的决策应由多学科肿瘤委员会根据现行临床指南作出。
临床怎么用
- 本指南旨在协助核医学科医生治疗和管理接受放射性栓塞治疗的患者。
- 放射性栓塞的决策应由多学科肿瘤委员会根据现行临床指南作出。
- 指南并非僵化规则或实践要求,也不应被用于确立法律照护标准;具体操作或行动方案的最终判断应由医疗专业人员结合每例患者的具体情况作出。
- 尽责的执业者可根据患者状况、可用资源限制或指南发布后的知识或技术进步,负责任地采用与指南不同的行动方案。
局限性
- 指南并非僵化规则或实践要求,也不应被用于确立法律照护标准。
- 遵循这些指南并不能确保准确诊断或成功结局。
- 医学实践涉及人类状况的多样性和复杂性,无法始终达到最适当的诊断或确定预测特定治疗反应。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Primary liver tumours (i.e. hepatocellular carcinoma (HCC) or intrahepatic cholangiocarcinoma (ICC)) are among the most frequent cancers worldwide. However, only 10-20% of patients are amenable to curative treatment, such as resection or transplant. Liver metastases are most frequently caused by colorectal cancer, which accounts for the second most cancer-related deaths in Europe. In both primary and secondary tumours, radioembolization has been shown to be a safe and effective treatment option. The vast potential of personalized dosimetry has also been shown, resulting in markedly increased response rates and overall survival. In a rapidly evolving therapeutic landscape, the role of radioembolization will be subject to changes. Therefore, the decision for radioembolization should be taken by a multidisciplinary tumour board in accordance with the current clinical guidelines. The purpose of this procedure guideline is to assist the nuclear medicine physician in treating and managing patients undergoing radioembolization treatment. PREAMBLE: The European Association of Nuclear Medicine (EANM) is a professional non-profit medical association that facilitates communication worldwide among individuals pursuing clinical and research excellence in nuclear medicine. The EANM was founded in 1985. These guidelines are intended to assist practitioners in providing appropriate nuclear medicine care for patients. They are not inflexible rules or requirements of practice and are not intended, nor should they be used, to establish a legal standard of care. The ultimate judgment regarding the propriety of any specific procedure or course of action must be made by medical professionals taking into account the unique circumstances of each case. Thus, there is no implication that an approach differing from the guidelines, standing alone, is below the standard of care. To the contrary, a conscientious practitioner may responsibly adopt a course of action different from that set out in the guidelines when, in the reasonable judgment of the practitioner, such course of action is indicated by the condition of the patient, limitations of available resources or advances in knowledge or technology subsequent to publication of the guidelines. The practice of medicine involves not only the science but also the art of dealing with the prevention, diagnosis, alleviation and treatment of disease. The variety and complexity of human conditions make it impossible to always reach the most appropriate diagnosis or to predict with certainty a particular response to treatment. Therefore, it should be recognised that adherence to these guidelines will not ensure an accurate diagnosis or a successful outcome. All that should be expected is that the practitioner will follow a reasonable course of action based on current knowledge, available resources and the needs of the patient to deliver effective and safe medical care. The sole purpose of these guidelines is to assist practitioners in achieving this objective.
引用
- Weber M, Lam M, Chiesa C, et al. EANM procedure guideline for the treatment of liver cancer and liver metastases with intra-arterial radioactive compounds. Eur J Nucl Med Mol Imaging. 2022. PMID: 35146577. doi:10.1007/s00259-021-05600-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。